The text starts here.

News Release

October 26, 2006
For Print (PDF 42KB)

Eisai Announces Completion of Acquisition of Four Oncology-Related Products from Ligand

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey, Chairman and CEO: Hajime Shimizu) announce on October 25, 2006 (U.S. Eastern Time) the completion of Eisai's acquisition of four oncology-related products from Ligand Pharmaceuticals (Headquarters: California, Chairman and interim CEO: Henry F. Blissenbach) based on the agreement signed on September 7, 2006 after having cleared the approval process by the government authorities including the Federal Trade Comission (FTC).

In the United States, Eisai Inc. assumed as of October 25, 2006 (the U.S. Eastern Time) the product distribution responsibilities concerning the four acquired products, ONTAK(R) (denileukin diftitox), Targretin(R) (bexarotene) capsules, Targretin(R) (bexarotene) gel 1% and Panretin(R) (alitretinoin) gel 0.1%. In Europe, Targretin(R) (bexarotene) capsules and Panretin(R) (alitretinoin) gel 0.1% will be supplied to the partner companies for distribution in the territory. In addition, certain Ligand personnel are being offered employment by Eisai Inc.

Oncology is one of Eisai's long-standing therapeutic areas of focus per its 5th medium-term business plan “Dramatic Leap Plan”. The strategic acquisition of these four products will help to serve to establish global oncology business as the company prepares for the introduction of its own pipeline products.

Eisai is rapidly promoting new drug development in oncology and strengthening the company's marketing and sales operations in order to develop its global oncology business. With the enhanced oncology-related products, Eisai is committed to creating the value for patients and increasing benefits to patients and their families.

Corporate Communications Department
Eisai Co., Ltd.
TEL: +81-3-3817-5036